Direct Factor Xa and direct thrombin inhibitors: A clinical trial update

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 4, 2009, Pages 497-508

  Turpie, Alexander G G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant; Clinical trial; Oral

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; ARH 067637; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; HIRULOG; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; RAZAXABAN; RITONAVIR; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

BLEEDING; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; EMBOLISM; FOOD; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; PRESCRIPTION; PROTEIN FUNCTION; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FACTOR XA; HUMANS; MOLECULAR STRUCTURE; THROMBIN; THROMBOEMBOLISM;

EID: 67649976737     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 133(6 Suppl):381S-453S.
2. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 133(6 Suppl):454S-545S.
3. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ, American College of Chest Physicians: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 133(6 Suppl):546S-592S.
4. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA, American College of Chest Physicians: Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest(2008) 133(6 Suppl):708S-775S.
5. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG, American College of Chest Physicians: Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 133(6 Suppl):670S-707S.
6. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty: American Academy of Orthopaedic Surgeons, Rosemont, IL, USA (2007). www.aaos.org/ Research/guidelines/PE-guideline.pdf
7. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guidelines 46: National Institute for Health and Clinical Excellence, London UK (2007). www.nice.org.uk/nicemedia/pdf/ CG046NICEguideline.pdf
8. Prophylaxis of venous thromboembolism. A national clinical guideline. SIGN Publication number 62: Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh, Scotland (2002). www.sign. ac.uk/pdf/sign62.pdf
9. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J: American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients? Chest (2009) 135(2):513-520.
10. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecularweight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 119(1 Suppl):64S-94S.
11. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 332(20):1330-1335.
12. sanofi-aventis. Lovenox (enoxaparin sodium injection) prescribing information: Sanofi-Aventis LLC, Bridgewater, NJ, USA (2007). products.sanofi-aventis.us/lovenox/lovenox.pdf
13. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J: Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs (2002) 11(3):397-407.
14. Daly AK: Pharmacogenomics of anticoagulants: Steps toward personal dosage. Genome Med (2009) 1(1):10. ·· Coumarin anticoagulants, such as warfarin, are widely used clinically, but currently dosing is determined individually because of variations in genetic factors that affect dose requirements. This paper discusses whole genome association studies, confirming that the main genes important in warfarin response are CYP2C9 and VKORC1.
15. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl):204S-233S.
16. Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE: Patients' perspectives on taking warfarin: Qualitative study in family practice. BMC Fam Pract (2004) 5:15-23.
17. Hirsh J, O'Donnell M, Eikelboom JW: Beyond unfractionated heparin and warfarin: Current and future advances. Circulation (2007) 116(5):552-560.
18. Hirsh J: Current anticoagulant therapy - Unmet clinical needs.Thromb Res (2003) 109(Suppl 1):S1-S8.
19. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol (1999) 19(9):2251-2262.
20. McBride BF: A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.J Clin Pharmacol (2005) 45(9):1004-1017. ·· Chronic anticoagulation represents a clinical challenge for the healthcare community, which balances morbidity and mortality benefits against interindividual variability. This review highlights the differences among oral anticoagulants currently in development, and clarifies their role in the context of the benefits and limitations of established anticoagulants.
21. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D et al: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood(2007) 110(5):1511-1515.
22. Esmon CT, Esmon NL, Le Bonniec BF, Johnson AE: Protein C activation. Methods Enzymol (1993) 222:359-385.
23. Tarzami ST, Wang G, Li W, Green L, Singh JP: Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost (2006) 4(3):656-663. · Endothelial progenitor cells have an important role in vascular response to injury and ischemia. Results from these studies provided evidence for a novel activity of thrombin and protease-activated receptor-1 on bone marrow progenitor cell proliferation and endothelial progenitor cell differentiation, suggesting their potential role in vascular regeneration and the recanalization of thrombus.
24. Vesey DA, Cheung CW, Kruger WA, Poronnik P, Gobe G, Johnson DW: Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells.Kidney Int (2005) 67(4):1315-1329.
25. Vergnolle N, Hollenberg MD, Wallace JL: Pro- and anti-inflammatory actions of thrombin: A distinct role for proteinase-activated receptor-1 (PAR1). Br J Pharmacol (1999) 126(5):1262-1268.
26. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, METHRO III Study Group: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.Thromb Haemost (2003) 89(2):288-296.
27. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: The EXPRESS study. J Thromb Haemost (2003) 1(12):2490-2496.
28. Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW: Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost (2003) 1(10):2119-2130.
29. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.N Engl J Med (2003) 349(18):1703-1712.
30. Schulman S, Wahlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med (2003) 349(18):1713-1721. · For patients with VTE, secondary prevention with VKAs is not extended beyond 6 months because of the risk of major bleeding. Treatment for 18 months with the novel oral anticoagulant ximelagatran did not increase bleeding, but increased alanine aminotransferase levels. Ximelagatran was withdrawn from the market in 2006.
31. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS et al: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. J Am Med Assoc (2005) 293(6):681-689.
32. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet (2003) 362(9397):1691-1698.
33. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. J Am Med Assoc (2005) 293(6):690-698.
34. First launch for Astrazeneca's Exanta™ (ximelagatran): the first oral anticoagulant in new class of direct thrombin inhibitors (DTIs): AstraZeneca plc, London, UK (2004). www.astrazeneca.com/ media/latest-press- releases/2004/2283?itemId=3891913
35. AstraZeneca Decides to Withdraw Exanta™. AstraZeneca plc, London, UK (2006). www.astrazeneca.com/media/latest-pressreleases/ 2006/5217?itemId=3891692
36. Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA: Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol (2008) 172(2):309-320. ·· Coagulation proteases were suggested to play a role in the pathogenesis of tissue remodeling and fibrosis. This study indicates that in addition to a role in coagulation, FXa-dependent protease-activated receptor-2 cleavage might be involved in the progression of tissue fibrosis and remodeling.
37. Mann KG, Brummel K, Butenas S: What is all that thrombin for?J Thromb Haemost (2003) 1(7):1504-1514.
38. Lassen MR, Davidson BL, Gallus AS, Pineo G, Ansell J, Deitchman D: A phase II randomized, double-blind, five-arm, parallelgroup, dose-response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood (2003) 102:Abs 41.
39. Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S: Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol (2007) 47(11): 1398-1407. · Rivaroxaban is a novel oral direct FXa inhibitor. This study demonstrated that rivaroxaban strongly inhibited platelet-induced thrombin generation after the activation of the coagulation pathway or platelets, even in the presence of minimal FXa inhibition in plasma.
40. Xarelto®: Summary of product characteristics: Bayer Schering Pharma AG, Berlin, Germany (2008). www.xarelto.com/scripts/pages/ en/information-on-xarelto/summary-of-product-characteristics/ index.php
41. Lang D, Weinz C, Schwarz T, Kubitza D, Mueck W: Metabolism and excretion of rivaroxaban - An oral, direct Factor Xa inhibitor - In rats, dogs and humans. Drug Metab Dispos (2009):doi: 10.1124/ dmd.108.025569.
42. Lang D, Freudenberger C, Weinz C: In vitro metabolism of rivaroxaban - An oral, direct Factor Xa inhibitor - In liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos (2009) 37(5):1046-1055.
43. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - An oral, direct Factor Xa inhibitor - After multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 61(12): 873-880.
44. Kubitza D, Becka M, Mueck W, Zuehlsdorf M: Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - An oral, direct Factor Xa inhibitor - Are not affected by aspirin.J Clin Pharmacol (2006) 46(9):981-990.
45. Kubitza D, Becka M, Mueck W, Zuehlsdorf M: Rivaroxaban (BAY 59- 7939) - An oral, direct Factor Xa inhibitor - Has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2007) 63(4):469-476.
46. Kubitza D, Becka M, Mueck W, Zuehlsdorf M: Co-administration of rivaroxaban - A novel, oral, direct Factor Xa inhibitor - And clopidogrel in healthy subjects. Eur Heart J (2007) 28(Suppl 1):189.
47. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P: Dose-escalation study of rivaroxaban (BAY 59-7939) - An oral, direct Factor Xa inhibitor - For the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res (2007) 120(5):685-693.
48. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators: Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.J Thromb Haemost (2006) 4(1):121-128.
49. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M: BAY 59-7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 3(11):2479-2486.
50. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators: A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 114(22):2374-2381.
51. Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P et al: Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thromb Haemost (2007) 97(6):931-937.
52. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 358(26):2765-2775.
53. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial.Lancet (2008) 372(9632):31-39.
54. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med(2008) 358(26):2776-2786.
55. Turpie AG, Bauer KA, Davidson B, Gent M, Kwong L, Lassen MR, Cushner F, Lotke P, Berkowitz SD, Bandel TJ, Misselwitz F et al: Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement: RECORD4. Am Soc Hematol Ann Meet Exposition (2008) 112(11):Abs 35.
56. Turpie AG, Lassen MR, Kakkar AK, Eriksson B, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Gent M: A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: Effect on symptomatic venous thromboembolism, death, and bleeding.Am Soc Hematol Ann Meet Exposition (2008) 112(11):Abs 36.
57. Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witowski A, Markov V, Burton P, Braunwald E: Randomized comparison of rivaroxaban, an oral direct Factor Xa inhibitor, with placebo in patients with acute coronary syndromes: The ATLAS ACS-TIMI 46 Trial. Circulation (2008) 118(22):2311.
58. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, Einstein-DVT Dose-Ranging Study investigators: A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The EINSTEIN-DVT Dose-Ranging Study. Blood(2008) 112(6):2242-2247.
59. ROCKET AF Executive Committee, Nessel C, Hacke W: Rivaroxaban - Once-daily, oral, direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. International Stroke Conference 2009, San Diego, CA, USA (2009).
60. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM: Apixaban, an oral, direct and highly selective Factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J Thromb Haemost (2008) 6(5):820-829. · Apixaban is an oral, direct, highly selective FXa inhibitor in late-stage clinical development. In in vivo rabbit models of thrombosis and hemostasis, apixaban was effective in the prevention of experimental thrombosis at doses that preserve hemostasis.
61. Weitz JI: Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost (2006) 96(3):274-284.
62. He K, He B, Grace JE, Xin B, Zhang D, Pinto DJ, Luettgen JM, Knabb RM, Lam PY, Wexler RR, Humphreys WG et al: Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood (2006) 108(11):Abs 910.
63. Frost C, Yu Z, Moore K, Nepal S, Barrett Y, Mosqueda-Garcia R, Shenker A: Apixaban, an oral direct Factor Xa inhibitor: Multiple-dose safety, pharmokinetics, and pharmaccodynamics in healthy subjects. J Thromb Haemost (2007) 5(Suppl 1):Abs P-M-664.
64. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D: The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost (2007) 5(12):2368-2375.
65. Lassen M, Gallus A, Pineo G, Raskob G, ADVANCE-1 Investigators: Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: The ADVANCE-1 trial. Am Soc Hematol Ann Meet Exposition (2008) 112(11):Abs 31.
66. Botticelli Investigators, Writing Committe, Buller H, Deitchman D, Prins M, Segers A: Efficacy and safety of the oral direct Factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Boticeli DVT dose-ranging study. J Thromb Haemost (2008) 6(8):1313-1318.
67. Alexander JH, Wallentin L, on behalf of the APPRAISE Investigators: Safety of the Factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: Results from the APPRAISE-1 dose guiding trial. Eur Heart J (2008) 29(Suppl):Abs 326.
68. Morishima Y, Furugohri T, Isobe K, Honda Y, Matsumoto C, Shiozaki Y, Muramatsu S, Sugiyama N, Shibano T: In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct Factor Xa inhibitor, DU-176b. Blood (2004) 104(11):Abs 1862.
69. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T: DU-176b, a potent and orally active Factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost (2008) 6(9):1542-1549. · Edoxaban is an oral direct FXa inhibitor that is currently in development. In in vivo and in vitro studies in rats and monkeys, edoxaban demonstrated a high oral bioavailability, and dose-dependently inhibited thrombus formation without prolonging bleeding time at antithrombotic doses.
70. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ: Antithrombotic effects of Factor Xa inhibition with DU-176b: Phase-I study of an oral, direct Factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost (2007) 98(4):883-888.
71. Fuji T, Fujita S, Tachibana S, Kawai Y: Randomized, doubleblind, multi-dose efficacy, safety and biomarker study of the oral Factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty. Am Soc Hematol Ann Meet Exposition (2008) 112(11):Abs 34.
72. Weitz JI, Connolly SJ, Kunitada S, Jin J, Patel I: Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation. Am Soc Hematol Ann Meet Exposition (2008) 112(11):Abs 33.
73. Iwatsuki Y, Shigenaga T, Moritani Y, Suzuki M, Ishihara T, Hirayama F, Kawasaki T: Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. Blood (2006) 108(11): Abs 911.
74. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L, ONYX study group: A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost (2007) 5(8):1660-1665.
75. R&D pipeline (May 2009): Astellas Pharma Inc (2009). www.astellas.com/en/ir/library/pdf/4q2009-rd-en.pdf
76. Turpie AG: New oral anticoagulants in atrial fibrillation. Eur Heart J (2008) 29(2):155-165.
77. Abe K, Siu G, Edwards S, Lin PH, Zhu BY, Marzec U, Hanson S, Pak Y, Hollenbach S, Sinha U: Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral Factor Xa inhibitor. Blood (2006) 108(11):Abs 901.
78. Turpie AG, Gent M, Bauer K, Davidson BL, Fisher W, Huo M, Borow K, Frame VB, Michalsky C, Gretier DD, Romanko K, Sinha U: Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT).J Thromb Haemost (2007) 5:Abs T-652.
79. Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V: Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost (2004) 2(9):1573-1580.
80. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol(2005) 45(5):555-563. · Dabigatran etexilate is an oral, low molecular weight DTI. The pharmacokinetic characteristics (absorption, distribution and elimination) of a single 150-mg dose capsule were investigated, and results confirmed the suitability of this oral form of dabigatran for use in clinical trials.
81. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2008) 36(2):386-399.
82. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W: Structurebased design of novel potent nonpeptide thrombin inhibitors.J Med Chem (2002) 45(9):1757-1766. · The researchers designed a new structural class of nonpeptidic thrombin inhibitors based on the X-ray crystal structure of the peptidelike thrombin inhibitor NAPAP complexed with bovine thrombin. By using a 1,2,5-trisubstituted benzimidazole as the central scaffold, the foundations for the development of dabigatran were provided.
83. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med (2005) 353(10):1028-1040.
84. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 64(3):292-303.
85. Sanford M, Plosker GL: Dabigatran etexilate. Drugs (2008) 68(12):1699-1709.
86. Pradaxa® (dabigatran etexilate): Summary of product characteristics: Boehringer Ingelheim GmbH, Ingelheim, Germany (2008). www.pradaxa.com/Include/media/pdf/Pradaxa-SPC-EMEA. pdf
87. Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P et al: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost (2005) 3(1):103-111.
88. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR et al: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet (2007) 370(9591):949-956.
89. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J et al: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost (2007) 5(11):2178-2185.
90. RE-MOBILIZE Writing Committee, Ginsberg J, Davidson B, Comp P, Francis CW, Friedman R, Huo M, Liberman JR, Muntz J, Raskob GE, Clements ML et al: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.J Arthroplasty (2008) 24(1):1-9.
91. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost (2009) 101(1): 77-85.
92. Gyzander E, Deinum J: Enzyme kinetic characterization of the active form of the novel oral direct thrombin inhibitor AZD0837. [abstract]. J Thromb Haemost (2007) 5(Suppl 2):Abs P-S-066.
93. Hockings PD, Adler G, Palmer M, Andreasson AC, Elg M: The oral direct thrombin inhibitor AZD0837 reduces thrombus formation in a rat model. J Thromb Haemost (2007) 5(Suppl 2):Abs S-697.
94. Pehrsson S, Elg M: The antithrombotic effect of AR-HO67637, the active form of the novel oral direct thrombin inhibitor AZDO837, in rat models of arterial and venous thrombosis.J Thromb Haemost (2007) 5(Suppl 2):Abs P-W-637.
95. AstraZeneca plc: AstraZeneca PLC third quarter and nine months results 2008. Press Release (2008):October 30
96. Eriksson BI, Quinlan DJ, Weitz JI: Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development. Clin Pharmacokinet (2009) 48(1):1-22.
97. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K et al: Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin- 1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine- 3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa. J Med Chem (2007) 50(22):5339-5356.
98. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E: Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3- oxazolidin-5-yl} methyl) thiophene- 2-carboxamide (BAY 59-7939): An oral, direct Factor Xa inhibitor. J Med Chem (2005) 48(19):5900-5908.
99. Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J et al: Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl) benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious Factor Xa inhibitor. Bioorg Med Chem Lett (2009) 19(8):2179-2185.